MEI Pharma, Inc.
MEIP · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.03 | -0.07 |
| FCF Yield | -126.65% | -265.83% | -119.84% | -64.87% |
| EV / EBITDA | 0.09 | 0.58 | -1.21 | -0.93 |
| Quality | ||||
| ROIC | -103.09% | 44.04% | -36.08% | -48.66% |
| Gross Margin | 0.00% | 99.41% | 96.28% | 100.00% |
| Cash Conversion Ratio | 1.31 | -2.84 | 1.65 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 17.07% | 24.11% | 12.07% |
| Free Cash Flow Growth | 58.71% | 3.88% | -6.69% | -50.66% |
| Safety | ||||
| Net Debt / EBITDA | 1.03 | -0.14 | 0.13 | 0.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,019.11 | -1,232.92 | 90.08 |